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Abstract
Anaemia is a common complication in haemodialysis patients. This condition is 
associated to a decreased bone marrow production of erythrocytes, mainly due to 
the inability of the failing kidneys to secrete erythropoietin (EPO). The 
introduction of recombinant human EPO (rhEPO) therapy led to a significant 
reduction in anaemia and improved patients’ quality of life. However, there is a 
marked variability in the sensitivity to rhEPO, with up to 10-fold variability in 
dose requirements to achieve correction of anaemia. Approximately 5-10% of the 
patients show a marked resistance to rhEPO therapy. rhEPO resistance is 
associated to an increased morbidity and mortality of haemodialysis patients. 
In this paper a revision of the mechanisms underlying resistance to rhEPO 
therapy will be performed, with particular emphasis on inflammatory cytokines, 
leukocyte activation, iron status, and erythrocyte damage. 
© 2009 Journal of Nephrology and Renal Transplantation. All rights reserved 
1. Introduction 
Anaemia is a common complication that contributes to the burden of 
haemodialysis (HD) patients. It has also a negative impact on cardiovascular 
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system, cognitive function, exercise capacity and quality of life, resulting in a 
significant morbidity and mortality in these patients. The introduction of rhEPO 
therapy in the early 1990s for treatment of anaemia of HD patients has led to a 
significant reduction in anaemia and to an improvement in patients’ quality of 
life (1-4). There is, however, a marked variability in the sensitivity to rhEPO, 
with up to 10-fold variability in dose requirements to achieve correction of the 
anaemia. Furthermore, around 5-10% of the patients show a marked resistance to 
rhEPO therapy (2,4-6). The European Best Practice Guidelines define “resistance 
to rhEPO therapy” as a failure to achieve target haemoglobin levels (between 11 
and 12 g/dL) with maintained doses of rhEPO higher than 300 IU/Kg/week of 
epoetin or of higher doses than 1.5 μg/Kg/week of darbopoietin-alfa (7).  
The reasons for this variability in rhEPO response are unclear (4, 8-12). There 
are a lot of conditions reported as associated with rhEPO resistance, namely, 
inflammation, oxidative stress and iron deficiency, as major causes (4, 8-14), and 
blood loss, hyperparathyroidism, aluminium toxicity and vitamin B12 or folate 
deficiency, as minor causes. However, exclusion of these factors does not 
eliminate the marked variability in sensitivity to rhEPO (15).  
In this paper a revision of the mechanisms of resistance to rhEPO therapy will 
be performed, with particular emphasis on inflammatory cytokines, leukocyte 
activation, iron status, and erythrocyte damage. 
2. Inflammatory cytokines 
Inflammation is the physiological response to a variety of noxious stimuli such 
as tissue injury caused by infection or physical damage. It is a complex process 
that involves the participation of several cells and molecules, and may present 
different intensities and durations. 
Inflammation usually refers to a localised process. However, if the noxious 
stimulus is severe enough, distant systemic changes may also occur, and these 
changes are referred as “acute phase response”, which is accompanied by signs 
and symptoms such as fever, anorexia, and somnolence. This acute phase 
response may include neuroendocrine, metabolic and haematopoietic changes, as 
well as changes in non-protein plasma constituents (16). The haematopoietic 
response includes leukocytosis and leukocyte activation, thrombocytosis, and 
anaemia secondary to erythrocyte damage and/or decreased erythropoiesis (17). 
Inflammatory stimuli induces the release of cytokines, including tumour 
necrosis factor (TNF)-α, interleukin (IL) -1, IL-6, and interferon (IFN)-γ, which 
may be produced by several cells, including leukocytes, fibroblasts and 
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endothelial cells (18). This release of cytokines causes many systemic changes, 
including increased synthesis and release of positive acute-phase proteins, such 
as C-reactive protein (CRP) and fibrinogen, as well as the suppression of 
negative acute-phase proteins, such as albumin and transferrin (4,11,19). 
The causes for the inflammatory response in HD patients are not well clarified. 
There are several potential sources, including bacterial contamination of the 
dialyser, incompatibility with the dialyser membrane and infection of the 
vascular access. However, the dialysis procedure may only be partially 
responsible for the inflammatory response, because even patients with renal 
insufficiency who are not yet on dialysis present raised inflammatory markers, 
which rise further after starting regular HD treatment, suggesting that the disease 
per se triggers an inflammatory response (6,13,15). 
Along an inflammatory response, the iron from the erythropoiesis traffic is 
mobilised to storage sites within the reticuloendothelial system, inhibiting 
erythroid progenitor proliferation and differentiation, and blunting, therefore, the 
response to erythropoietin (EPO) (endogenous and/or exogenous). An 
erythropoiesis-suppressing effect has been also attributed to increased activity of 
pro-inflammatory cytokines reported in this inflammatory condition, and this 
relationship has been proposed as a potential factor associated to rhEPO therapy 
resistance (6,13,15,20). Actually, it was reported that pro-inflammatory 
cytokines, such as IL-1, IL-2, IL-4, IL-6, TNF-α and INF-γ diminish BFU-E and 
CFU-E cells, resulting in suppression of erythropoiesis (5,21,22). Moreover, it 
was reported (5) that serum derived from haemodialysed patients suppresses 
erythroid colony-forming response to EPO, in a manner that can be inhibited by 
antibodies against TNF-α and INF-γ. These data suggest a key role in the rhEPO 
response for these inflammatory mediators (8,11,23,24).  
Recently, our group demonstrated an activation of T-cells and an enhanced 
ability of this cells to produce Th1 related cytokines (IL-2, INF-γ and TNF-α) 
after short term in vitro stimulation, although these cytokines were undetectable 
in serum. This increased capacity to produce Th1 cytokines could justify, at least 
in part, the anaemia found in HD patients. However, this enhanced capacity to 
produce cytokines was not associated to the refractoriness to rhEPO therapy, as 
previously described in non-responders HD patients (11). We also demonstrated 
that non-responders patients presented higher C-reactive protein (CRP) and lower 
albumin serum levels as compared to responders (25), suggesting a relationship 
between resistance to rhEPO therapy and the inflammatory response (Table I).  
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Table 10- Inflammatory markers among HD patients (responders and non-responders to rhEPO therapy). 
 rhEPO 
responders 
rhEPO non-
responders 
White cell counts N N 
Neutrophils counts ↑ ↑ 
Albumin serum levels N ↓ 
CRP serum levels ↑ ↑↑ 
IL-6 serum levels ↑ ↑↑ 
Soluble IL-2 receptor serum 
levels 
↑ ↑ 
Elastase plasma levels ↑ ↑↑ 
N: normal values when compared with healthy controls; ↑: increase values when compared with healthy 
controls; ↓: decrease values when compared with healthy controls; ↑↑ increase values when compared with 
responders patients. Adapted from references 25 and 40. 
3. Leukocyte activation 
Leukocytosis and recruitment of circulating leukocytes into the affected areas 
are hallmarks of inflammation. Leukocytes are chimio-attracted to inflammatory 
regions and their transmigration from blood to the injured tissue is primarily 
mediated by the expression of cell-adhesion molecules in the endothelium, which 
interact with surface receptors on leukocytes (26,27). This leukocyte-endothelial 
interaction is regulated by a cascade of molecular steps that correspond to the 
morphological changes that accompany adhesion. At the inflammatory site, 
leukocytes release their granulation products and may exert them phagocytic 
capacities. 
In acute inflammation, the leukocyte infiltration is predominantly of 
neutrophils, whereas in chronic inflammation a mononuclear cell infiltration 
(predominantly macrophages and lymphocytes) is observed. Although leukocyte-
endothelial cell interaction is important for leukocyte extravasation and 
trafficking in physiological situations, there is increasing evidence that altered 
leukocyte-endothelial interactions are implicated in the pathogenesis of diseases 
associated with inflammation, possibly by damaging the endothelium or altering 
endothelial function (28,29). 
Leukocytosis is essential as the primary host defence, and neutrophils, the 
major leukocyte population of blood in adults, play a primordial role. It is well 
known that neutrophils have mechanisms that are used to destroy invading 
microorganisms. These cells use an extraordinary array of oxygen-dependent and 
oxygen-independent microbicidal weapons to destroy and remove infectious 
agents (30). Oxygen-dependent mechanisms involve the production of reactive 
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oxygen species (ROS), which can be microbicidal (31), and lead to the 
development of oxidative stress. Oxygen-independent mechanisms include 
chemotaxis, phagocytosis and degranulation. The generation of microbicidal 
oxidants by neutrophils results from the activation of a multiprotein enzyme 
complex known as the reduced nicotinamide adenine dinucleotide phosphate 
oxidase, which catalyzes the formation of superoxide anion (O2·–). Activated 
neutrophils also undergo degranulation, with the release of several components, 
namely, proteases (such as elastase) and cationic proteins (such as lactoferrin).  
Elastase is a member of the chymotrypsin superfamily of serine proteinases, 
expressed in monocytes and mast cells, but mainly expressed by neutrophils, 
where it is compartmentalized in the primary azurophil granules. The 
intracellular function of this enzyme is the degradation of foreign 
microorganisms that are phagocytosed by the neutrophil (32). Elastase can also 
degrade local extracellular matrix proteins (such as elastin), remodel damaged 
tissue, and facilitate neutrophil migration into or through tissues. Moreover, 
elastase also modulates cytokine expression at epithelial and endothelial surfaces, 
up-regulating the production of cytokines, such as IL-6, IL-8, transforming 
growth factor β (TGF-β) and granulocyte-macrophage colony-stimulating factor 
(GM-CSF); it also promotes the degradation of cytokines, such as IL-1, TNF-α 
and IL-2. There is evidence in literature that high levels of elastase are one of the 
major pathological factors in the development of several chronic inflammatory 
lung conditions (33).  
Plasma lactoferrin is predominantly neutrophil derived and its presence in the 
specific granules is often used to identify these types of granules. Lactoferrin is 
also found in other granules, in the tertiary granules, though in lower 
concentrations (34-37). Lactoferrin is a multifunctional iron glycoprotein, which 
is known to exert a broad-spectrum primary defence activity against bacteria, 
fungi, protozoa and viruses. It can bind to large amounts of free iron. The iron 
bound to lactoferrin is taken up by activated macrophages, which express specific 
lactoferrin receptors. During inflammation, this causes iron deprivation of the 
erythroid precursors, which fail to express lactoferrin receptors (38). Other 
mechanisms in which lactoferrin is implicated include a growth regulatory 
function in normal cells, coagulation, and perhaps cellular adhesion modulation 
(39). 
There are no considerable data concerning to the correlation between 
leukocyte activation and resistance to rhEPO therapy, particularly to the 
neutrophil activation. We recently found that patients under HD, particularly 
non-responders patients, present higher elastase plasma levels, compared to 
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healthy controls (40). Moreover, we demonstrated neutrophil activation, 
triggered by HD procedure. However, the HD procedure does not explain the 
higher elastase levels found in non-responders patients. Moreover, we found 
statistically significant positive correlations between elastase levels and CRP, 
suggesting that the rise in elastase levels is part of the inflammatory process 
found in HD patients, being particularly enhanced in non-responders. The 
statistically significant correlation that we also found between elastase levels and 
weekly rhEPO doses also corroborate this hypothesis; in fact, non-responders to 
rhEPO therapy patients requiring higher weekly rhEPO doses to achieve target 
hemoglobin levels, are also associated with an increased inflammatory process. 
The increase plasma levels of elastase found in HD patients can be associated 
to alterations in erythrocyte membrane proteins, which could decrease 
erythrocyte half life in HD patients, particularly in non-responders, and 
consequently increase the degree of anaemia in these patients. 
 
Table II - Iron status markers among HD patients (responders and non-responders to rhEPO therapy). 
 rhEPO 
responders 
rhEPO non-
responders 
Haemoglobin concentration ↑ ↓↓ 
Mean cell haemoglobin N ↓ 
Mean cell haemoglobin 
concentration 
N ↓ 
RDW (red cell distribution 
width) 
↑ ↑↑ 
Transferrin saturation  N N 
Ferritin serum levels ↑ ↑ 
Transferrin serum levels ↓ ↓ 
s-TfR serum levels N ↑ 
Prohepcidin serum levels ↑ ↑ 
N: normal values when compared with healthy controls; ↑: increase values when compared with healthy 
controls; ↓: decrease values when compared with healthy controls; ↑↑ increase values when compared with 
responders patients; ↓↓ decrease values when compared with responders patients. Adapted from reference 61. 
4. Iron status 
Iron is an essential trace element that is required for growth and development 
of living organisms, but excess of free iron is toxic for the cell (41-43). Mammals 
lack a regulatory pathway for iron excretion, and iron balance is maintained by 
the tight regulation of iron absorption from the intestine (42,44). The intestinal 
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iron absorption is regulated by the level of body iron stores and by the amount of 
iron needed for erythropoiesis (41,42,44,45).  
In HD patients, iron absorption is similar to that found in healthy individuals; 
however, when under rhEPO therapy, the absorption of iron increases as much as 
5 times (46). This increased iron absorption is not sufficient to compensate for 
the iron lost during the HD procedure, and with the frequent blood draws 
performed on these patients. For this reason, intravenous iron administration has 
become a standard therapy for most patients receiving rhEPO. To avoid iron 
overload, with potentially harmful consequences, there is a need to monitor iron 
therapy by performing regular blood tests reflecting body’s iron stores.  
Recently, a complex regulatory network that governs iron traffic emerged, and 
points to hepcidin as a major evolutionary conserved regulator of iron 
distribution (47-49). This small hormone produced by the mammalian liver has 
been proposed as a central mediator of dietary iron absorption. High levels of 
hepcidin were found to be associated with a decrease in both iron uptake from the 
small intestine and in iron release from macrophages; a decreased placental iron 
transport was also observed (50). 
The synthesis of hepcidin is stimulated by inflammation and iron overload. 
The in vitro stimulation of fresh human hepatocytes by pro-inflammatory IL-6 
showed strong induction of hepcidin mRNA, indicating that this cytokine may be 
an important mediator of hepcidin induction in inflammation (51-57). It is 
synthesized as preprohepcidin, a protein with 84 amino acids. This peptide is 
cleaved leading to prohepcidin with 60 aminoacids, which is further processed 
giving rise to the 25 aminoacids protein, hepcidin (51,52).  
Hepcidin was reported to bind to the transmembrane iron exporter ferroportin, 
which is present on macrophages, on the basolateral site of enterocytes, and also 
on hepatocytes. It has been demonstrated in vitro that hepcidin induces the 
internalization and degradation of ferroportin, a crucial protein for cellular iron 
export (53). By diminishing the effective number of iron exporters on the 
membrane of enterocytes and of macrophages, hepcidin suppresses iron uptake 
and release, respectively. This is the phenotype of ferroportin disease, where iron 
accumulation is observed mainly in macrophages and often combined with 
anaemia (54). 
This increased hepcidin expression during inflammation explains sequestration 
of iron in the macrophages and inhibition of intestinal iron absorption, the two 
hallmarks of the anaemia of inflammation, which is normocytic or microcytic 
iron-refractory (47,50,52).  This decreased availability in iron may be a host 
defence mechanism against invading microorganisms.  
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The biological importance of the precursor molecule of hepcidin, named 
prohepcidin, in regulating iron metabolism, is still undetermined. However, there 
is some evidence that prohepcidin levels are a reliable indicator of hepcidin 
levels and activity (50,52,58,59). 
Hepcidin synthesis is regulated by inflammation, a common finding in HD 
patients. Thus, increased levels of prohepcidin have been reported in HD patients 
(50,52,58-60).  
We recently demonstrated that HD patients non-responders to rhEPO therapy 
present a mild to moderate anaemia, even with the administration of higher 
rhEPO doses (61). This anaemia is hypochromic [decreased mean cell 
haemoglobin (MCH) and mean cell haemoglobin concentration (MCHC)], and is 
associated with a more accentuated anisocytosis than in responder patients. 
Considering that all patients, in our study, were under iron and folate 
prophylactic therapies, and, that iron status and vitamin B12 serum levels were 
normal, these changes could not be attributable to a deficiency in these 
erythropoietic nutrients. Actually, the HD patients non-responders to rhEPO 
therapy seem to present a “functional” iron deficiency, characterized by the 
presence of adequate iron stores as defined by conventional criteria, but 
apparently with an inability to sufficiently mobilize iron to adequately support 
erythropoiesis. In fact, no statistically significant differences were found in serum 
iron status markers between the groups of patients (responders and non-
responders), except for the soluble transferrin receptor (s-TfR), which was 
statistically significant higher among non-responders (Table II). This 
“functional” iron deficiency is reflected by a decrease in MCH and in MCHC, 
and by a more accentuated anisocytosis (high RDW) in non-responders patients. 
Furthermore, the inverse correlation that we have found between CRP and mean 
cell volume, MCH, serum iron and transferrin saturation, are in agreement with 
the observations that the chronic inflammation enhanced in non-responders, may 
lead to trapping of iron within the macrophages and to a reduction in serum iron 
levels. Additionally, HD patients non-responders to rhEPO therapy presented 
lower prohepcidin serum levels when compared with responders. As previously 
referred, hepcidin is up-regulated by inflammation; however, on the other hand 
EPO downregulates liver hepcidin expression (62). As non-responders patients 
were treated with much higher doses of rhEPO compared with responders, the 
lower prohepcidin levels found in those patients could be explained by this 
mechanism.  
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5. Erythrocyte damage 
The erythrocyte, presenting a limited biosynthesis capacity, suffers and 
accumulates physical and/or chemical changes, which become more pronounced 
with cell aging, and whenever an unusual physical or chemical stress develops 
(63).  
The erythrocyte membrane is a complex structure comprising a lipidic bilayer, 
integral proteins and the skeleton. Spectrin is the major protein of the 
cytoskeleton, and, therefore, the major responsible for erythrocyte shape, 
integrity and deformability. It links the cytoskeleton to the lipid bilayer, by 
vertical protein interactions with the transmembrane proteins, band 3 and 
glicophorin A (64). In the vertical protein interaction of spectrin with band 3 are 
also involved ankyrin (also known as band 2.1) and protein 4.2. A normal linkage 
of spectrin with the other proteins of the cytoskeleton assures normal horizontal 
protein interactions.  
Erythrocytes are physically stressed during the HD process, and metabolically 
stressed by the unfavourable plasmatic environment, due to metabolite 
accumulation, and by the high rate of haemoglobin autoxidation, due to the 
increase in haemoglobin turnover, a physiologic compensation mechanism 
triggered in case of anaemia (64,65). The erythrocytes are, therefore, 
continuously challenged to sustain haemoglobin in its reduced functional form, 
as well as to maintain the integrity and deformability of the membrane. 
When haemoglobin is denatured, it links to the cytoplasmic pole of band 3, 
triggering its aggregation and leading to the formation of strictly lipidic portions 
of the membrane, poorly linked to the cytoskeleton. These cells are probably 
more prone to undergo vesiculation (loss of poorly linked membrane portions) 
whenever they have to circulate through the haemodialysis membranes or the 
microvasculature. Vesiculation may, therefore, lead to modifications in the 
erythrocyte membrane of HD patients (66,67).  
Erythrocytes that develop intracellular defects earlier during their life span are 
removed prematurely from circulation (68,69). The removal of senescent or 
damaged erythrocytes seems to involve the development of a senescent 
neoantigen on the plasma membrane surface, marking the cell for death. This 
neoantigen is immunologically related to band 3 (70). The deterioration of the 
erythrocyte metabolism and/or of its antioxidant defences may lead to the 
development of oxidative stress within the cell, allowing oxidation and linkage of 
haemoglobin to the cytoplasmatic domain of band 3, promoting its aggregation, 
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the binding of natural antiband 3 autoantibodies and complement activation, 
marking the erythrocyte for death. 
The band 3 profile [high molecular weight aggregates (HMWAg), band 3 
monomer and proteolytic fragments (Pfrag)], differs among younger, damaged 
and/or senescent erythrocytes. Older and damaged erythrocytes present with 
higher HMWAg and lower Pfrag. Younger erythrocytes show reduced HMWAg 
and higher Pfrag (69). Moreover, several diseases, known as inflammatory 
conditions, presented abnormal band 3 profiles, suggestive of oxidative stress 
development (68,69,71).   
HD patients present a reduction in erythrocyte membrane spectrin, though 
without statistically significance, was found in non-responders patients. This 
spectrin deficiency was accompanied by the production of hypocromic and 
anisocytic erythrocytes, and this anisocytosis could reflect an even more 
enhanced change in membrane protein interactions in non-responders (73,74). 
Non-responders patients also showed a decrease in Pfrag and in Pfrag/band 3 
monomer ratio (Fig. 1) and a trend to higher values of membrane bond 
haemoglobin (75), suggesting that they present a higher erythrocyte damage that 
may result from an even more adverse plasmatic microenvironment. When 
studying the differences in membrane protein composition before and after the 
haemodialysis procedure, we found that this spectrin reduction was enhanced in 
the non-responder group (76); moreover, we observed that this could be 
associated to an enhanced inflammation process and/or to the interaction with 
proteases released by neutrophils as we also found significant rise in elastase, 
product of leukocyte activation.  
6. Conclusions 
Although the etiology of resistance to rhEPO therapy is still unknown, 
inflammation seems to have an important role in its pathophysiology. Resistance 
to rhEPO therapy is also associated with “functional” iron deficiency, higher 
elastase plasma levels, and alterations in erythrocyte membrane protein structure 
and in band 3 profile. 
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The exact origins of the inflammatory process remain unclear. We speculate 
that the release of elastase during the HD procedure could have an important role 
in amplifying the inflammatory process in HD patients, particularly in non-
responders (Fig 2). Furthermore, this elastase release could also have an 
important role in the alterations found in erythrocyte membrane protein structure 
and in band 3 profile, further contributing to worsening of anaemia (Fig 2). The 
inflammatory process, the rhEPO doses administrated and the lactoferrin release 
during haemodialysis could have an important role in iron uptake from the small 
intestine, in the release of iron from macrophages and, finally, in the availability 
of iron for erythropoiesis.. 
Further studies are needed to understand the rise in inflammation with the 
associated need in higher doses of rhEPO and reduced iron availability. It will be 
also important to clarify the mechanism of lymphocyte loss, by studying the role 
of IL-7 levels and/or the peripheral lymphocyte apoptosis; the effect of higher 
levels of elastase in the inflammatory process, and in the alterations in 
erythrocyte membrane protein composition and in band 3 profile. Of great 
importance would be also the development of animal studies, by using a rat 
Figure 6 - Illustration of two band 3 profiles. C: control; P: HD patient; HMW Ag: high molecular 
weight aggregates; Pfrag: proteolytic fragments. 
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model of chronic renal failure, as some histological and molecular studies, cannot 
be performed in humans, such as the erythropoietic and renal studies. 
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